Share on StockTwits

Investment analysts at Sanford C. Bernstein raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $65.00 to $107.00 in a note issued to investors on Wednesday. Sanford C. Bernstein’s price objective would indicate a potential upside of 14.40% from the company’s current price.

In other Vertex Pharmaceuticals news, EVP Peter Mueller sold 7,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $68.31, for a total value of $512,325.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of other firms have also recently commented on VRTX. Analysts at Leerink Swann raised their price target on shares of Vertex Pharmaceuticals from $100.00 to $125.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at HC Wainwright downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday. They now have a $85.00 price target on the stock, down previously from $105.00. Finally, analysts at Needham & Company LLC raised their price target on shares of Vertex Pharmaceuticals from $95.00 to $115.00 in a research note on Tuesday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Hold” and an average target price of $95.44.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 93.53 on Wednesday. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $98.80. The stock’s 50-day moving average is $69.89 and its 200-day moving average is $73.39. The company’s market cap is $22.091 billion. Vertex Pharmaceuticals also was the recipient of some unusual options trading activity on Monday. Stock traders acquired 13,082 call options on the company. This is an increase of 235% compared to the average daily volume of 3,903 call options.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.82 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.